My Treatment Approach: Targeting Genetic Alterations in Tumors: Clinical Scenarios and Precision Oncology Approaches

Experts discuss the importance of NGS testing for identifying actionable alterations like RET fusions in solid tumors and when to consider testing.

Dr. Lukas presents a case of a young man with a BRAF-fused brain tumor treated with a MEK inhibitor. Explored tailored therapy targeting the underlying genetic alteration.

Dr. Schreck brings forward a compelling case of a teenage female with BRAF V600E mutant ganglioglioma. Witness how the identification of this specific genetic alteration paved the way for treated with targeted therapy.

Experts discuss the challenges in adopting targeted therapies like BRAF/MEK inhibitors for BRAF-altered gliomas and gangliogliomas and strategies to facilitate their integration into practice.

Dr. Subbiah and Dr. Lukas review the efficacy and safety data from key clinical trials like ROAR and MATC evaluating tumor agnostic therapies across different tumor types.

Dr. Subbiah presents a pancreatic cancer case with PRKARA1A- RET fusion treated with selpercatinib in a clinical trial.

The panel discusses the impact of tumor agnostic approvals like BRAF/MEK inhibitors on the treatment landscape, unmet needs address and sequencing therapies like RET inhibitors in cancers like pancreatic cancer.

The panelists provide their perspective on best practices for keeping up with the rapidly evolving RET fusion landscape and unmet needs to be addressed by future RET-targeted therapies beyond lung cancer.